Remedium with reference to FierceBiotech informs that on the findings of the clinical research studies, the new trial three-in-one inhaler from AstraZeneca has outperformed in terms of efficiency Symbicort and other two-drug inhalers.
It is expected that application for registration of the medicine will be submitted in the second part of the current year.
1.8 K of patients with the moderate and severe form of COPD were selected for participation in the researches. The patients got the experimental triple combination PT010 or the control medicines depending on the randomization group twice a day for 24 weeks.
Patients in the other arms took one of AstraZeneca’s dual-combination COPD therapies, Symbicort and Bevespi Aerosphere, or an experimental two-drug inhaler, PT009.
PT010 outperformed the other drugs in terms of efficiency (forced expiratory volume). The active substances of PT010 are budesonide, glycopyrronium, formoterol fumarate.

BaDM - We work for you!

Regional offices